All In Biotech

Drug Trial Radar · NCT07285902

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of HRS9531 Injection Versus Semaglutide Injection in Subjects With Obesity

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 572 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

572

Actual

Start

Dec 25, 2025

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity

Conditions

  • Obesity

Interventions

  • HRS9531 injectionDrug

    HRS9531 injection

  • Semaglutide InjectionDrug

    Semaglutide Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from baseline in body weight after 52 weeks of treatmentTime frame: 52 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Chiness PLA General Hospital

    Beijing, Beijing Municipality, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.